NICE rejects Opdivo (nivolumab) as a treatment for renal cell carcinoma.- BMS
NICE,( The National Institute for Health and Care Excellence),has rejected Opdivo (nivolumab) from BMS as a cost effective treatment for renal cell carcinoma (kidney cancer). NICE did not accept BMS analyses of the data from CHECKMATE- 025 study which demonstrated superiority of Opdivo over Afinitor (everolimus) from Novartis which is the standard treatment for renal cell carcinoma.
NICE also did not consider Opdivo as cost effective at a price of �91,000 compared to Affinitor costs at �39,000 although in QALY (quality adjusted life year) terms Opdivo efficacy was 2.3 compared to 1.69 for Afinitor. NICE contrasted the Opdivo pricing with discounts offered by Pfizer for Inlyta.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins